Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials

OncoTargets and Therapy
Xuan HeYuanmin Li

Abstract

Several clinical trials have performed risk-benefit analyses comparing docetaxel and pemetrexed or docetaxel and vinca alkaloid, but the efficacy and safety remain uncertain. The aim was to conduct a meta-analysis to compare the efficacy and safety of docetaxel and pemetrexed or docetaxel and vinca alkaloid for non-small-cell lung cancer. This meta-analysis of Phase III randomized controlled trials was performed after searching PubMed, Embase, the Cochrane Library, and the ISI Web of Knowledge for randomized controlled trials. Outcome analyses were overall survival, progression-free survival, and overall response rate with 95% confidence intervals and major grade 3/4 toxicity. Seven eligible trials involving 2,080 patients were retrieved for analysis. Docetaxel enhanced progression-free survival and overall response rate compared with vinca alkaloid as first-line treatment (P<0.05). However, there was no difference between docetaxel and pemetrexed as both first-line and second-line treatment (P>0.05). With regard to the grade 3/4 toxicity, compared with pemetrexed, docetaxel led to higher neutropenia and febrile neutropenia (P<0.05), but there was no difference in non-hematological toxicity (P>0.05). Docetaxel led to a lower ra...Continue Reading

Citations

Feb 24, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sun Min LimJoo-Hang Kim
Sep 24, 2016·Expert Review of Respiratory Medicine·A MatikasA Kotsakis
Aug 18, 2018·BMJ Case Reports·Caren van RoekelTycho M T W Lock
Jan 29, 2019·Combinatorial Chemistry & High Throughput Screening·Chu-Hui Ru, Yan-Bing Zhuang
Aug 28, 2021·International Journal of Molecular Sciences·Mi-So JeongSeong-Gyu Ko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.